The FDA review of the biologics license application includes data on SC isatuximab as both manual injection and via an ...

The evolving treatment landscape in polycythemia vera (PV) is shifting from a focus on hematocrit control to a more ...

To address the limitations of binary pCR classification, Pusztai and colleagues developed the residual cancer burden (RCB) ...

Dr Bazhenova presents TRUST data at AACR 2026, showing taletrectinib reached a 46.1-month PFS and 89.8% ORR in TKI-naive, ...

Learn how myeloma experts sequence CAR T and bispecifics, boost MRD-negative rates, and why academic-community teamwork ...

ASCO's updated thyroid cancer guidelines help clinicians navigate rapidly evolving systemic therapies, from VEGF inhibitors to BRAF-targeted agents. Thyroid cancer management has undergone rapid ...

During a live event, participants discuss barriers to access and bridging strategies for tumor-infiltrating lymphocytes in ...

Rashmi Chugh, MD, describes the background for a study of ozekibart in Ewing sarcoma. Rashmi Chugh, MD, of the University of ...

FDA fast track designation supports expedited development and regulatory interaction for BBO-11818 in advanced KRAS-mutant ...

The cancer antigen therapy mRNA-4359 yielded a high rate of antitumor responses in combination with pembrolizumab (Keytruda) ...

Clinical trials show subcutaneous isatuximab is preferred by patients, enabling faster dosing, home treatment, and paving the ...

The FDA has granted a priority review to the supplemental Biologics License Application for enfortumab/pembrolizumab to all ...